JPWO2020223702A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223702A5 JPWO2020223702A5 JP2021565064A JP2021565064A JPWO2020223702A5 JP WO2020223702 A5 JPWO2020223702 A5 JP WO2020223702A5 JP 2021565064 A JP2021565064 A JP 2021565064A JP 2021565064 A JP2021565064 A JP 2021565064A JP WO2020223702 A5 JPWO2020223702 A5 JP WO2020223702A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- galectin
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841732P | 2019-05-01 | 2019-05-01 | |
| US62/841,732 | 2019-05-01 | ||
| PCT/US2020/031181 WO2020223702A1 (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531408A JP2022531408A (ja) | 2022-07-06 |
| JPWO2020223702A5 true JPWO2020223702A5 (es) | 2023-05-11 |
Family
ID=73029403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565064A Pending JP2022531408A (ja) | 2019-05-01 | 2020-05-01 | 抗ガレクチン９抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220178930A1 (es) |
| EP (1) | EP3962954A4 (es) |
| JP (1) | JP2022531408A (es) |
| CN (1) | CN114026126B (es) |
| AU (1) | AU2020266677A1 (es) |
| CA (1) | CA3138863A1 (es) |
| SG (1) | SG11202112112UA (es) |
| WO (2) | WO2020223704A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6873445B2 (ja) | 2017-10-27 | 2021-05-19 | ニューヨーク ユニバーシティ | 抗ガレクチン−９抗体及びその使用 |
| CA3138863A1 (en) * | 2019-05-01 | 2020-11-05 | New York University | Anti-galectin-9 antibodies and uses thereof |
| US20240109968A1 (en) * | 2020-11-20 | 2024-04-04 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| IL308014A (en) * | 2021-04-30 | 2023-12-01 | Puretech Lyt Inc | Anti-galectin-9 antibodies and their therapeutic uses |
| IL311796A (en) * | 2021-10-01 | 2024-05-01 | Beigene Switzerland Gmbh | Anti-galectin-9 antibodies and their therapeutic uses |
| WO2024006933A1 (en) * | 2022-06-29 | 2024-01-04 | Puretech Lyt, Inc. | Treatment of hematological malignancies with antibodies inhibiting galectin-9 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9050352B2 (en) * | 2003-10-16 | 2015-06-09 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
| EA200701211A1 (ru) * | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
| US20070237764A1 (en) * | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CN101977934B (zh) * | 2008-01-18 | 2014-09-17 | 健泰科生物技术公司 | 用于靶向k63连接的多聚遍在蛋白的方法和组合物 |
| JP2011528804A (ja) * | 2008-07-18 | 2011-11-24 | オラジェニックス，インコーポレイテッド | 結腸直腸癌の検出及び治療のための組成物 |
| EP2638070B1 (en) * | 2010-11-10 | 2016-10-19 | F.Hoffmann-La Roche Ag | Methods and compositions for neural disease immunotherapy |
| WO2012077811A1 (ja) * | 2010-12-09 | 2012-06-14 | 株式会社ガルファーマ | ガレクチン９を分泌する細胞、その製造方法及びその用途 |
| FR3021970B1 (fr) * | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| AU2015343425A1 (en) * | 2014-11-04 | 2017-05-25 | Dana-Farber Cancer Institute, Inc. | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses |
| US10294294B2 (en) * | 2015-09-10 | 2019-05-21 | Albert Einstein College Of Medicine | Synthetic antibodies to BAX and uses thereof |
| EP3463452A1 (en) * | 2016-05-24 | 2019-04-10 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
| WO2019006007A1 (en) * | 2017-06-27 | 2019-01-03 | Novartis Ag | POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF |
| JP6873445B2 (ja) * | 2017-10-27 | 2021-05-19 | ニューヨーク ユニバーシティ | 抗ガレクチン−９抗体及びその使用 |
| CA3134942A1 (en) * | 2019-03-25 | 2020-10-01 | New York University | Anti-galectin-9 antibodies and uses thereof |
| CA3138863A1 (en) * | 2019-05-01 | 2020-11-05 | New York University | Anti-galectin-9 antibodies and uses thereof |
| CN114502241A (zh) * | 2019-08-01 | 2022-05-13 | 纽约大学 | 抗半乳凝素-9抗体和化疗剂的联合癌症疗法 |
| US20240287195A1 (en) * | 2020-10-26 | 2024-08-29 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma |
| US20240109968A1 (en) * | 2020-11-20 | 2024-04-04 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| WO2022109302A1 (en) * | 2020-11-20 | 2022-05-27 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| JP2024519449A (ja) * | 2021-04-30 | 2024-05-14 | ピュアテック・エル・ワイ・ティ・インコーポレイテッド | がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 |
| IL308014A (en) * | 2021-04-30 | 2023-12-01 | Puretech Lyt Inc | Anti-galectin-9 antibodies and their therapeutic uses |
-
2020
- 2020-05-01 CA CA3138863A patent/CA3138863A1/en active Pending
- 2020-05-01 EP EP20798582.1A patent/EP3962954A4/en active Pending
- 2020-05-01 US US17/607,879 patent/US20220178930A1/en active Pending
- 2020-05-01 CN CN202080047488.7A patent/CN114026126B/zh active Active
- 2020-05-01 US US17/607,878 patent/US20220185896A1/en active Pending
- 2020-05-01 AU AU2020266677A patent/AU2020266677A1/en active Pending
- 2020-05-01 SG SG11202112112UA patent/SG11202112112UA/en unknown
- 2020-05-01 JP JP2021565064A patent/JP2022531408A/ja active Pending
- 2020-05-01 WO PCT/US2020/031184 patent/WO2020223704A1/en active Application Filing
- 2020-05-01 WO PCT/US2020/031181 patent/WO2020223702A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| JP6283665B2 (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2019515008A5 (es) | ||
| JP2014533279A5 (es) | ||
| JP2020508317A5 (es) | ||
| JP2018518454A5 (es) | ||
| JP2016530323A5 (es) | ||
| EP1976886A1 (en) | Means and methods for the treatment of tumorous diseases | |
| TW201902514A (zh) | Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2020158544A (ja) | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 | |
| JP2020506728A5 (es) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| JP2020500161A5 (es) | ||
| JPWO2020223702A5 (es) | ||
| Jäeger et al. | Rituximab (anti‐CD20 monoclonal antibody) as consolidation of first‐line CHOP chemotherapy in patients with follicular lymphoma: a phase II study | |
| JP2020507596A5 (es) | ||
| WO2024026019A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| JPWO2019160755A5 (es) | ||
| WO2023009434A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |